InMed Pharmaceuticals (NASDAQ:INM) seeks the permission of local authorities in Israel, Australia, and Serbia to conduct phase 2 clinical studies of INM-755 cream to cure EB (Epidermolysis Bullosa). The company also applies with Ethics Committees (ECs) and National...
